New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
15:54 EDTJNJ, GSK, PCYCPharmacyclics announces trial results of Imbruvica vs. ofatumumab
Pharmacyclics (PCYC) announced trial results of the first Phase III study, RESONATE, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA, ibrutinib, versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL. Patients receiving IMBRUVICA realized a significant improvement in progression free survival, PFS, overall survival, OS, and overall response rate, ORR, as compared to patients receiving ofatumumab (GSK). The RESONATE data will be discussed in the official Press Program by lead investigator Dr. John Byrd from The Ohio State University Medical Center at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. This release corresponds to abstract LBA7008. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
News For PCYC;GSK;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
08:00 EDTGSKGlaxo has cut 40% of China sales reps in wake of scandal, Reuters reports
Subscribe for More Information
07:34 EDTGSKGlaxoSmithKline starts phase III study of sirukumab in Giant Cell Arteritis
Subscribe for More Information
November 25, 2015
11:29 EDTGSKStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
November 24, 2015
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJ, GSKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use